In an industry where public equity financing is becoming progressively more costly for small U.S. biotechs, companies are looking to public markets overseas to obtain access to capital, taking advantage of less stringent corporate governance obligations and lower admission standards. This panel will take a look at financing trends in European markets as well as explore creative financing strategies when effectuating an IPO is out of the question.



Objectives:

Educate the audience as to new financing alternatives such as those that exist through the London Stock Exchange's Alternative Investment Market (AIM) marketplace and through alternative funding approaches such as royalty deals, equity lines and those offered through Symphony Capital.

Educate biotech companies on how to present themselves to these new funding sources.

Educate audience on what to do once a transaction format has been selected.